Clinical trials: Metastasis Colorectal Cancer
Colorectal Neoplasms
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
The purpose of this study is to determine the safety of regorafenib, an antiangiogenic drug, when combined with radioembolization using SIR-Spheres® microspheres in the treatment of colorectal cancer (CRC) that has spread to the…
- Trial name
- NCT02195011
- Testing
- SIR-Spheres, Regorafenib
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- SCRI Development Innovations, LLC
Liver Metastasis, Colorectal Cancer
Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
The correlation between the values of angiogenesis-related growth factors in plasma and efficacy, and biomarkers relevant as prognostic factors or predictive factors for sensitivity or resistance to treatment will be examined…
- Trial name
- ATOM ES (NCT01834014)
- Testing
- Bevacizumab, Cetuximab, L-OHP
- Where
- Japan
- Volunteers
- 110 people
- Sponsor
- EPS Corporation
Colorectal Cancer, Non Resectable Metastasis
Response Prediction in Metastasized Colorectal Cancer Using Intratumoral Thymidylate Synthase
The aim of the study was to evaluate the feasibility of TS determination in a multicenter trial setting using a central facility for measurement and confirm its role as predictive factor for 5-FU treatment in MCRC.
- Conditions
- Colorectal Cancer, Non Resectable Metastasis, Reference Lesion, Biopsy
- Trial name
- FOGT5 (NCT01212718)
- Testing
- FUFA, systemic chemotherapy
- Where
- Germany
- Volunteers
- 168 people
- Sponsor
- University of Ulm
Advanced Solid Tumor, Metastatic Solid Tumor
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
- Trial name
- NCT06974110
- Testing
- MOMA-341, Irinotecan, Immunotherapy
- Where
- 15 sites in United States, Australia
- Volunteers
- 132 people
- Sponsor
- MOMA Therapeutics
Metastatic Colon Cancer
ZETA : Prospective Observational Study
Primary objective Evaluate the efficacy in terms of progression-free survival (PFS) of aflibercept in combination with FOLFIRI in patients treated routinely for metastatic colorectal cancer (mCRC) after failure of treatment with…
- Trial name
- ZETA (NCT03730558)
- Testing
- aflibercept + FOLFIRI
- Where
- 2 sites in France
- Volunteers
- 120 people
- Sponsor
- Recherche clinique
Efficacy, Self, Safety Issues
First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer
This is a prospective, multi-center, randomized controlled clinical intervention study, aiming to explore the effectiveness and safety of mfolfox6 and hlx04 regimens combined with slulimumab as first-line treatment for MSS-type…
- Conditions
- Efficacy, Self, Safety Issues, Colo-rectal Cancer
- Trial name
- NCT06491355
- Testing
- mfolfox6 and hlx04 regimen and Serplulimab, mfolfox6 and hlx04 regimen
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Sir Run Run Shaw Hospital
Colorectal Cancer, Neoplasm Metastasis
Proof-of-concept Study of Blood Markers of Tumor Dissemination in Patients With Versus Without Intestinal Polyps
The study authors hypothesize that in patients with intestinal polyps, tumor cells could disseminate and circulating factors could be secreted by the polyp.
- Conditions
- Colorectal Cancer, Neoplasm Metastasis, Disseminated Cancer
- Trial name
- EARDIS (NCT05648240)
- Testing
- Blood test
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Gastric Cancer, Colon Cancer
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
This study intends to explore the role of PD1/PDL1 antibody with selective combination of Sintilimab, IBI310 and Lenvatinib in organ preservation in non-metastatic dMMR/MSI-H gastric or colon cancers with mismatch repair…
- Conditions
- Gastric Cancer, Colon Cancer, MSI-H, DMMR Cancer
- Trial name
- NCT06580574
- Testing
- PD1/PDL1 antibody monotherapy, up to 24 weeks, Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks, Radical surgery
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Peking University
Colorectal Cancer Metastatic
Local Consolidative Therapy in Colorectal Cancer
This is a Phase II randomized multisite trial to study the effect of a combination of local consolidative therapy with systemic therapy in subjects with oligometastatic colorectal cancer who have progressed on the first line of…
- Trial name
- NCT05062720
- Testing
- Local consolidative therapy
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Solid Tumor, Breast Cancer
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant…
- Conditions
- Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT05989724
- Testing
- SON-DP
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Qurgen Inc.
Liver Metastases
Treatment of Liver Metastases With Electrochemotherapy
The aim of the study is to evaluate toxicity and effectiveness of electrochemotherapy with bleomycin in treatment of liver metastases of colorectal cancer in clinical study phase I and II.
- Trial name
- ECTJ (NCT01264952)
- Testing
- Electrochemotherapy
- Where
- Slovenia
- Volunteers
- 16 people
- Sponsor
- Institute of Oncology Ljubljana
Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer
The goal of this clinical trial is to demonstrate the non-inferiority of trifluridine/tipiracil + regorafenib vs trifluridine/tipiracil + bevacizumab in terms of progression free survival in patients with refractory metastatic…
- Trial name
- REGTAS-2 (NCT06992648)
- Testing
- Trifluridine/Tipiracil + Regorafenib, Trifluridine/tipiracil + bevacizumab
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Cancer Metastatic
Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network
National trial, multicenter, randomized, phase II comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy (CT) to systemic chemotherapy alone in patients with liver-only…
- Trial name
- SULTAN (NCT03164655)
- Testing
- Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil
- Where
- 4 sites in France
- Volunteers
- 20 people
- Sponsor
- UNICANCER
Colorectal Cancer, Metastatic Cancer
Cryosurgery in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
RATIONALE: Cryosurgery for liver metastases may have fewer side effects and improve recovery. PURPOSE: Phase II trial to study the effectiveness of cryosurgery for patients with unresectable liver metastases from colorectal…
- Trial name
- NCT00002997
- Testing
- cryosurgery
- Where
- 3 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Colorectal Cancer Metastatic
An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
To evaluate the safety and efficacy of HRS-2189 combined with Adebrelimab and BP102 in the treatment of metastatic colorectal cancer
- Trial name
- NCT07061210
- Testing
- HRS-2189, Adebrelimab, BP102
- Volunteers
- 20 people
- Sponsor
- Fudan University
Colorectal Cancer, Significant Bowel Pathology
Optimising Colorectal Cancer Patient Pathways
Bowel cancer (colorectal cancer) is the 4th most common cancer in Scotland. Approximately 4,000 cases are diagnosed annually. Cancer-related deaths in Scotland are higher than other UK nations.
- Trial name
- NCT07430540
- Testing
- Additional FIT testing
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Edinburgh
Rectal Adenocarcinoma, Recurrent Rectal Carcinoma
TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) when given together with radiation therapy in treating patients with rectal cancer that has…
- Conditions
- Rectal Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IV Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7
- Trial name
- NCT03297710
- Testing
- Quality-of-Life Assessment, Radiation Therapy, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Colorectal Cancer, Metastasis
Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)
The purpose of this study is to compare progression free survival rates of metastasized colorectal cancer patients refractory or intolerant to systemic therapy with fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF therapy and…
- Trial name
- SUNRISE-CRC (NCT03909724)
- Testing
- Sunitinib Malate, TAS 102
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Amsterdam UMC, location VUmc
Metastatic Colorectal Cancer
PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer
PROSPECT-C is a phase II study investigating the molecular markers of response or resistance to anti-epidermal growth factor receptor (EGFR) antibodies.
- Trial name
- PROSPECT-C (NCT02994888)
- Testing
- Cetuximab
- Where
- United Kingdom
- Volunteers
- 47 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer
- Trial name
- NCT00207155
- Testing
- Cetuximab
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.